Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J, Chen G, Wang D, Wang G, Lu S, Feng J, Li W, Li P, Lanzarotti C, Chessari S, Zhang L. Chang J, et al. Among authors: lanzarotti c. Cancer Med. 2020 Jul;9(14):5134-5142. doi: 10.1002/cam4.3123. Epub 2020 May 30. Cancer Med. 2020. PMID: 32472742 Free PMC article. Clinical Trial.
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M. Zhang L, et al. Among authors: lanzarotti c. Ann Oncol. 2018 Feb 1;29(2):452-458. doi: 10.1093/annonc/mdx698. Ann Oncol. 2018. PMID: 29092012 Free PMC article. Clinical Trial.
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W. Calcagnile S, et al. Among authors: lanzarotti c. Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11. Support Care Cancer. 2013. PMID: 23748441
Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study.
Calcagnile S, Lanzarotti C, Gutacker M, Jakob-Rodamer V, Peter Kammerer K, Timmer W. Calcagnile S, et al. Among authors: lanzarotti c. Clin Pharmacol Drug Dev. 2015 Sep;4(5):377-86. doi: 10.1002/cpdd.192. Epub 2015 May 29. Clin Pharmacol Drug Dev. 2015. PMID: 27137147 Clinical Trial.
Netupitant PET imaging and ADME studies in humans.
Spinelli T, Calcagnile S, Giuliano C, Rossi G, Lanzarotti C, Mair S, Stevens L, Nisbet I. Spinelli T, et al. Among authors: lanzarotti c. J Clin Pharmacol. 2014 Jan;54(1):97-108. doi: 10.1002/jcph.198. Epub 2013 Nov 8. J Clin Pharmacol. 2014. PMID: 24122871 Free PMC article. Clinical Trial.
20 results